BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
6 Well known Ladies' Fragrances On the planet - 2Vote In favor of Your Favored Keeping an eye on
- 3Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how
- 4Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- 5Esteem Stuffed Gaming Workstations to Consider
- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- Violence 'never part' of break-in plan, court told
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- Tech for Learning: Online Courses and Instructive Apparatuses
- Trump signs a law returning whole milk to school lunches
- Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- My skin feels drier, my lips thinner and my makeup heavier. How do I adjust my routine for aging skin?
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- 6 US States for Fly Fishing
